Trade Exelixis, Inc. - EXEL CFD

Add to favourite

23.23

1.84%

0.12

Low: 23.06

High: 23.4

Market Trading Hours* (UTC) Opens on Wednesday at 13:30

Mon - Fri: 13:30 - 20:00

Summary
Historical Data
Events
Income Statement
Balance Sheet
Cash Flow

Trading сonditions

Spread

0.12

Long position overnight fee

-0.026179%

Short position overnight fee

0.003957%

Overnight fee time

21:00 (UTC)

Min traded quantity

Currency

USD

Margin

Stock exchange

United States of America

Commission on trade

*Information provided by Capital.com

Exelixis Inc ESG Risk Ratings

High Medium Low Negligible

‘B’ score indicates good relative ESG performance and above average degree of transparency in reporting material ESG data publicly.

More ESG coverage

Key Stats

Prev. Close*	22.8
Open*	23.06
1-Year Change*	21.69%
Day's Range*	23.06 - 23.4
52 wk Range	16.15-24.34
Average Volume (10 days)	2.57M
Average Volume (3 months)	46.99M
Market Cap	6.93B
P/E Ratio	79.36
Shares Outstanding	310.97M
Revenue	1.77B
EPS	0.28
Dividend (Yield %)	N/A
Beta	0.54
Next Earnings Date	Feb 6, 2024

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

Last Week
Last Month
Last Year
Last two Years
Max

Daily
Weekly
Monthly

Date	Close	Change	Change (%)	Open	High	Low
Apr 23, 2024	23.22	0.32	1.40%	22.90	23.41	22.86
Apr 22, 2024	22.80	0.29	1.29%	22.51	23.00	22.48
Apr 19, 2024	22.46	0.09	0.40%	22.37	22.65	22.17
Apr 18, 2024	22.41	-0.47	-2.05%	22.88	23.17	22.40
Apr 17, 2024	22.82	0.08	0.35%	22.74	23.23	22.74
Apr 16, 2024	22.76	0.37	1.65%	22.39	23.02	22.39
Apr 15, 2024	22.63	-0.13	-0.57%	22.76	22.99	22.57
Apr 12, 2024	22.74	0.17	0.75%	22.57	22.99	22.56
Apr 11, 2024	22.60	-0.50	-2.16%	23.10	23.10	22.35
Apr 10, 2024	23.63	0.16	0.68%	23.47	23.74	23.32
Apr 9, 2024	23.68	0.62	2.69%	23.06	23.69	23.06
Apr 8, 2024	23.28	0.38	1.66%	22.90	23.37	22.57
Apr 5, 2024	23.07	-0.24	-1.03%	23.31	23.39	23.03
Apr 4, 2024	23.42	-0.27	-1.14%	23.69	23.90	23.32
Apr 3, 2024	23.62	0.41	1.77%	23.21	23.78	23.09
Apr 2, 2024	23.27	-0.13	-0.56%	23.40	23.53	23.18
Apr 1, 2024	23.62	0.10	0.43%	23.52	23.65	23.06
Mar 28, 2024	23.63	-0.13	-0.55%	23.76	23.92	23.45
Mar 27, 2024	23.81	0.19	0.80%	23.62	23.84	23.56
Mar 26, 2024	23.54	0.01	0.04%	23.53	23.72	23.52

Exelixis, Inc. Events

Time (UTC)	Country	Event
Tuesday, April 30, 2024
Time (UTC) 10:59	Country US	Event Q1 2024 Exelixis Inc Earnings Release Q1 2024 Exelixis Inc Earnings Release Forecast - Previous -
Thursday, May 30, 2024
Time (UTC) 16:00	Country US	Event Exelixis Inc Annual Shareholders Meeting Exelixis Inc Annual Shareholders Meeting Forecast - Previous -
Tuesday, July 30, 2024
Time (UTC) 10:59	Country US	Event Q2 2024 Exelixis Inc Earnings Release Q2 2024 Exelixis Inc Earnings Release Forecast - Previous -

View all events

Annual
Quarterly

	2022	2021	2020	2019	2018
Total revenue	1611.06	1434.97	987.538	967.775	853.826
Revenue	1611.06	1434.97	987.538	967.775	853.826
Cost of Revenue, Total	57.909	52.873	36.272	33.097	26.348
Gross Profit	1553.15	1382.1	951.266	934.678	827.478
Total Operating Expense	1409.58	1148.3	877.478	598.305	414.971
Selling/General/Admin. Expenses, Total	459.856	401.715	293.355	228.244	206.366
Research & Development	891.813	693.716	547.851	336.964	182.257
Unusual Expense (Income)					0
Operating Income	201.484	286.666	110.06	369.47	438.855
Interest Income (Expense), Net Non-Operating	33.065	7.672	19.865	27.959	12.84
Net Income Before Taxes	234.352	294.154	130.837	398.109	452.092
Net Income After Taxes	182.282	231.063	111.781	321.012	690.07
Net Income Before Extra. Items	182.282	231.063	111.781	321.012	690.07
Net Income	182.282	231.063	111.781	321.012	690.07
Income Available to Common Excl. Extra. Items	182.282	231.063	111.781	321.012	690.07
Income Available to Common Incl. Extra. Items	182.282	231.063	111.781	321.012	690.07
Diluted Net Income	182.282	231.063	111.781	321.012	690.07
Diluted Weighted Average Shares	324.556	322.359	318.001	315.009	312.803
Diluted EPS Excluding Extraordinary Items	0.56163	0.71679	0.35151	1.01906	2.20608
Diluted Normalized EPS	0.56163	0.71679	0.35151	1.01906	2.20608
Total Extraordinary Items
Dilution Adjustment					0
Other, Net	-0.197	-0.184	0.912	0.68	0.397

	Jun 2023	Mar 2023	Dec 2022	Sep 2022	Jun 2022
Total revenue	469.848	408.788	423.917	411.738	419.427
Revenue	469.848	408.788	423.917	411.738	419.427
Cost of Revenue, Total	17.705	14.315	15.92	15.305	13.481
Gross Profit	452.143	394.473	407.997	396.433	405.946
Total Operating Expense	391.998	379.958	471.995	329.125	335.721
Selling/General/Admin. Expenses, Total	141.723	131.397	119.251	114.983	122.759
Research & Development	232.57	234.246	336.824	198.837	199.481
Operating Income	77.85	28.83	-48.078	82.613	83.706
Interest Income (Expense), Net Non-Operating	22.541	19.502	16.988	9.498	4.757
Other, Net	-0.005	-0.054	-0.337	-0.069	0.045
Net Income Before Taxes	100.386	48.278	-31.427	92.042	88.508
Net Income After Taxes	81.178	40.028	-30.173	73.21	70.672
Net Income Before Extra. Items	81.178	40.028	-30.173	73.21	70.672
Net Income	81.178	40.028	-30.173	73.21	70.672
Income Available to Common Excl. Extra. Items	81.178	40.028	-30.173	73.21	70.672
Income Available to Common Incl. Extra. Items	81.178	40.028	-30.173	73.21	70.672
Diluted Net Income	81.178	40.028	-30.173	73.21	70.672
Diluted Weighted Average Shares	327.305	326.279	323.257	325.066	324.904
Diluted EPS Excluding Extraordinary Items	0.24802	0.12268	-0.09334	0.22522	0.21752
Dividends per Share - Common Stock Primary Issue	0	0	0	0	0
Diluted Normalized EPS	0.24802	0.12268	-0.09334	0.22522	0.21752

Annual
Quarterly

	2022	2021	2020	2019	2018
Total Current Assets	1618.76	1834.75	1445.4	1011.19	897.016
Cash and Short Term Investments	1308.47	1467.07	1206.54	852.243	693.334
Cash & Equivalents	501.195	647.169	319.217	266.501	314.775
Short Term Investments	807.273	819.905	887.319	585.742	378.559
Total Receivables, Net	214.784	282.65	160.875	120.173	178.827
Accounts Receivable - Trade, Net	214.784	282.65	160.875	120.173	162.771
Total Inventory	33.299	27.493	20.973	12.886	9.838
Prepaid Expenses	62.211	57.53	57.011	25.888	15.017
Total Assets	3071.49	2616.24	2137.33	1885.67	1422.29
Property/Plant/Equipment, Total - Net	345.435	149.153	110.394	90.727	56.764
Goodwill, Net	63.684	63.684	63.684	63.684	63.684
Long Term Investments	756.731	371.112	332.306	534.749	157.187
Other Long Term Assets, Total	285.218	195.878	185.554	185.32	247.635
Total Current Liabilities	324.359	337.59	204.658	142.746	105.472
Accounts Payable	32.667	24.258	23.632	11.581	10.901
Accrued Expenses	180.077	231.403	115.896	90.725	60.53
Notes Payable/Short Term Debt	0	0	0	0	0
Current Port. of LT Debt/Capital Leases					0.049
Other Current Liabilities, Total	111.615	81.929	65.13	40.44	33.992
Total Liabilities	583.062	405.624	258.22	199.7	134.833
Total Long Term Debt	0	0	0	0	0.079
Other Liabilities, Total	258.703	68.034	53.562	56.954	29.282
Total Equity	2488.43	2210.61	1879.11	1685.97	1287.45
Preferred Stock - Non Redeemable, Net	0	0		0	0
Common Stock	0.324	0.319	0.312	0.305	0.3
Additional Paid-In Capital	2536.85	2427.56	2321.9	2241.95	2168.22
Retained Earnings (Accumulated Deficit)	-34.225	-216.507	-447.57	-559.351	-880.363
Other Equity, Total	-14.521	-0.758	4.476	3.069	-0.701
Total Liabilities & Shareholders’ Equity	3071.49	2616.24	2137.33	1885.67	1422.29
Total Common Shares Outstanding	323.951	318.842	311.627	304.831	299.876
Other Current Assets, Total					0
Capital Lease Obligations					0.079
Property/Plant/Equipment, Total - Gross	406.307	189.984	145.078	116.287	74.073
Accumulated Depreciation, Total	-60.872	-40.831	-34.684	-25.56	-17.309
Note Receivable - Long Term	1.659	1.665

	Sep 2023	Jun 2023	Mar 2023	Dec 2022	Sep 2022
Total Current Assets	1443.37	1590.53	1637.62	1618.76	1841.62
Cash and Short Term Investments	1103.39	1266.81	1313.13	1308.47	1546.99
Cash & Equivalents	396.859	464.48	540.597	501.195	675.286
Short Term Investments	706.528	802.335	772.536	807.273	871.706
Total Receivables, Net	248.113	232.818	233.923	214.784	215.015
Accounts Receivable - Trade, Net	248.113	232.818	233.923	214.784	215.015
Total Inventory	24.978	28.635	29.908	33.299	26.711
Prepaid Expenses	66.891	62.259	60.654	62.211	52.903
Total Assets	2976.91	3142.47	3143.36	3071.49	2961.37
Property/Plant/Equipment, Total - Net	121.039	115.004	116.212	110.624	107.909
Goodwill, Net	63.684	63.684	63.684	63.684	63.684
Long Term Investments	811.68	838.615	805.133	756.731	550.253
Other Long Term Assets, Total	536.503	533.382	519.325	520.029	397.541
Total Current Liabilities	376.816	339.617	327.597	324.359	301.733
Accounts Payable	26.45	25.994	32.621	32.667	30.572
Accrued Expenses	171.509	150.433	139.085	162.418	147.261
Notes Payable/Short Term Debt	0	0	0	0	0
Other Current Liabilities, Total	178.857	163.19	155.891	129.274	123.9
Total Liabilities	629.29	614.53	588.223	583.062	469.97
Total Long Term Debt	0	0	0	0	0
Other Liabilities, Total	252.474	274.913	260.626	258.703	168.237
Total Equity	2347.62	2527.94	2555.14	2488.43	2491.4
Preferred Stock - Non Redeemable, Net	0	0	0	0	0
Common Stock	0.311	0.32	0.325	0.324	0.323
Additional Paid-In Capital	2487.37	2530.87	2558.3	2536.85	2512.67
Retained Earnings (Accumulated Deficit)	-126.049	11.186	5.803	-34.225	-4.052
Other Equity, Total	-14.012	-14.437	-9.289	-14.521	-17.538
Total Liabilities & Shareholders’ Equity	2976.91	3142.47	3143.36	3071.49	2961.37
Total Common Shares Outstanding	310.97	320.253	324.985	323.951	322.541
Note Receivable - Long Term	0.635	1.256	1.387	1.659	0.364

Annual
Quarterly

	2022	2021	2020	2019	2018
Net income/Starting Line	182.282	231.063	111.781	321.012	690.07
Cash From Operating Activities	362.614	400.804	208.982	526.956	415.72
Cash From Operating Activities	20.875	13.63	9.141	8.348	4.915
Deferred Taxes	-60.358	46.529	15.265	71.002	-244.111
Non-Cash Items	232.614	148.595	112.935	59.509	44.609
Cash Taxes Paid	127.87	12.96	4.115	7.873	10.677
Cash Interest Paid				0	0
Changes in Working Capital	-12.799	-39.013	-40.14	67.085	-79.763
Cash From Investing Activities	-524.414	-42.884	-131.215	-587.247	-297.85
Capital Expenditures	-27.706	-64.225	-30.345	-12.834	-33.297
Other Investing Cash Flow Items, Total	-496.708	21.341	-100.87	-574.413	-264.553
Cash From Financing Activities	0.586	-14.801	-25.132	12.553	9.691
Financing Cash Flow Items	-23.3	-39.108	-50.018	-9.946	-7.574
Issuance (Retirement) of Stock, Net	23.886	24.307	24.886	22.499	17.278
Issuance (Retirement) of Debt, Net				0	-0.013
Net Change in Cash	-161.214	343.119	52.635	-47.738	127.561

	Mar 2023	Dec 2022	Sep 2022	Jun 2022	Mar 2022
Net income/Starting Line	40.028	182.282	212.455	139.245	68.573
Cash From Operating Activities	84.408	362.614	288.92	178.849	147.719
Cash From Operating Activities	6.855	20.875	14.929	9.266	4.49
Deferred Taxes	0	-60.358	0	0	15.318
Non-Cash Items	56.149	232.614	101.039	55.183	22.724
Changes in Working Capital	-18.624	-12.799	-39.503	-24.845	36.614
Cash From Investing Activities	-49.592	-524.414	-278.632	-209.681	-74.539
Capital Expenditures	-12.024	-27.706	-25.989	-17.946	-5.609
Other Investing Cash Flow Items, Total	-37.568	-496.708	-252.643	-191.735	-68.93
Cash From Financing Activities	4.586	0.586	2.589	4.627	0.205
Financing Cash Flow Items	-2.557	-23.3	-16.091	-11.164	-4.686
Issuance (Retirement) of Stock, Net	7.143	23.886	18.68	15.791	4.891
Net Change in Cash	39.402	-161.214	12.877	-26.205	73.385

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission

Leverage

1:1

20
100
500
1000
10000

Investment

Trade size (Leverage x Investement):

Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Exelixis Company profile

Exelixis, Inc., a biotechnology company, engages in the discovery, development, and commercialization of new medicines to enhance care and outcomes for people with cancer. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. It also offers COTELLIC tablets, an inhibitor of MEK in combination with vemurafenib for the treatment of patients with BRAF V600E or V600K mutation-positive advanced melanoma in the United States; and in combination with vemurafenib in other territories, including the European Union, Switzerland, Canada, Australia, and Brazil. Exelixis, Inc. has collaboration and license agreements with Ipsen Pharma SAS, Genentech, Inc., GlaxoSmithKline, Bristol-Myers Squibb Company, Sanofi, Merck, and Daiichi Sankyo Company Limited for the development and commercialization of various compounds and programs. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was founded in 1994 and is headquartered in South San Francisco, California.

Industry:

Bio Therapeutic Drugs

1851 Harbor Bay Parkway
ALAMEDA
CALIFORNIA 94502
US

Income Statement

Annual
Quarterly

News

We’re partnering with Newsquawk

Filter out the noise and focus on the news that matters.

08:32, 23 April 2024

US Earnings Season: Tesla, Alphabet, Meta Platforms and Microsoft

The first lot of Wall Street’s mega-cap tech companies report in the coming week. We preview what to expect from Tesla, Alphabet, Meta, and Microsoft’s quarterly results.

15:56, 22 April 2024

Gold price in 2024: geopolitical tensions and rate-cut expectations keep XAU/USD supported

Investors are keeping a close eye on gold as the conflict in the Middle East escalates with a possibility of a full-scale regional war in the area.

07:56, 17 April 2024

US Earnings Season : JP Morgan, Citigroup, Wells Fargo

The first major US banks report quarterly earnings on Friday, April 12th, 2024. We preview what to expect from JP Morgan, Citigroup, and Wells Fargo's quarterly numbers.

16:03, 11 April 2024

Reserve Bank of New Zealand Preview: Rates expected to remain on hold as inflation fight continues

The Reserve Bank of New Zealand (RBNZ) meets on Wednesday, April 10, 2024. We preview what to expect from the meeting and its possible impact on the NZD/USD.

09:22, 11 April 2024

US CPI Preview: US inflation expected to grind lower amid fears about sticky prices

US CPI data is released on Wednesday, 10 April. We preview what to expect from the data, how it could influence US Federal Reserve policy, and analyse the NASDAQ (US Tech 100).

15:11, 9 April 2024

How escalating geopolitical tensions are impacting oil markets

The bullish momentum in oil prices remains strong as escalating geopolitical tensions raise concerns about supply.

13:34, 4 April 2024

People also watch

BTC/USD

66,798.60 Price

+0.590% 1D Chg, %

Trade Now

US100

17,604.00 Price

+0.490% 1D Chg, %

Trade Now

Gold

2,329.11 Price

+0.290% 1D Chg, %

Trade Now

XRP/USD

0.56 Price

-0.560% 1D Chg, %

Trade Now

Still looking for a broker you can trust?

Join the 610,000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading

Trade Exelixis, Inc. - EXEL CFD

Long position overnight fee

Short position overnight fee

Exelixis Inc ESG Risk Ratings

Exelixis, Inc. Events

Why choose Capital.com? Our numbers speak for themselves.

610K+

100K+

$100M+

$43M+

Start a global, multi-asset portfolio with an award-winning platform

Trading calculator

Exelixis Company profile

Income Statement

News

People also watch

Still looking for a broker you can trust?

Long position overnight fee	-0.0616%
Short position overnight fee	0.0137%
Overnight fee time	21:00 (UTC)
Spread	106.00

Long position overnight fee	-0.0262%
Short position overnight fee	0.0040%
Overnight fee time	21:00 (UTC)
Spread	1.8

Long position overnight fee	-0.0193%
Short position overnight fee	0.0111%
Overnight fee time	21:00 (UTC)
Spread	0.31

Long position overnight fee	-0.0753%
Short position overnight fee	0.0069%
Overnight fee time	21:00 (UTC)
Spread	0.01168